NO20090141L - Stabiliserte, farmasøytiske preparater som omfatter fesoterodin - Google Patents

Stabiliserte, farmasøytiske preparater som omfatter fesoterodin

Info

Publication number
NO20090141L
NO20090141L NO20090141A NO20090141A NO20090141L NO 20090141 L NO20090141 L NO 20090141L NO 20090141 A NO20090141 A NO 20090141A NO 20090141 A NO20090141 A NO 20090141A NO 20090141 L NO20090141 L NO 20090141L
Authority
NO
Norway
Prior art keywords
fesoterodine
pharmaceutical preparations
stabilized pharmaceutical
stabilized
isomalt
Prior art date
Application number
NO20090141A
Other languages
English (en)
Other versions
NO341980B1 (no
Inventor
Meike Irngartinger
Hans Lindner
Christoph Arth
Hans-Jurgen Mika
Michael Komenda
Fatima Bicane
Kerstin Paulus
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38521333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20090141(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of NO20090141L publication Critical patent/NO20090141L/no
Publication of NO341980B1 publication Critical patent/NO341980B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Den foreliggende søknad angår et farmasøytisk preparat som omfatter fesoterodin eller et farmasøytisk akseptabelt salt eller solvat derav og en stabilisator valgt fra gruppen som består av xylitol, sorbitol, polydekstrose, isomalt og dekstrose.
NO20090141A 2006-06-09 2009-01-09 Stabiliserte, farmasøytiske preparater som omfatter fesoterodin NO341980B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06011942 2006-06-09
EP06011943 2006-06-09
EP06011941 2006-06-09
PCT/EP2007/055582 WO2007141298A1 (en) 2006-06-09 2007-06-06 Stabilized pharmaceutical compositions comprising fesoterodine

Publications (2)

Publication Number Publication Date
NO20090141L true NO20090141L (no) 2009-01-09
NO341980B1 NO341980B1 (no) 2018-03-05

Family

ID=38521333

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090141A NO341980B1 (no) 2006-06-09 2009-01-09 Stabiliserte, farmasøytiske preparater som omfatter fesoterodin

Country Status (37)

Country Link
EP (1) EP2029134B1 (no)
JP (2) JP4743321B2 (no)
KR (1) KR101316773B1 (no)
CN (1) CN101466371B (no)
AP (1) AP2416A (no)
AR (1) AR061289A1 (no)
AT (1) ATE517619T1 (no)
AU (1) AU2007255408B2 (no)
BR (1) BRPI0712865B1 (no)
CA (1) CA2652712C (no)
CR (1) CR10494A (no)
CU (1) CU23850B1 (no)
CY (1) CY1111934T1 (no)
DK (1) DK2029134T3 (no)
EA (1) EA015909B9 (no)
EC (1) ECSP089010A (no)
ES (1) ES2370943T3 (no)
GT (1) GT200800276A (no)
HR (1) HRP20110776T1 (no)
IL (2) IL195732A (no)
MA (1) MA30504B1 (no)
MX (1) MX2008015736A (no)
MY (1) MY146574A (no)
NI (1) NI200800318A (no)
NL (1) NL2000690C2 (no)
NO (1) NO341980B1 (no)
NZ (1) NZ572616A (no)
PE (2) PE20120476A1 (no)
PL (1) PL2029134T3 (no)
PT (1) PT2029134E (no)
RS (1) RS51973B (no)
SI (1) SI2029134T1 (no)
TN (1) TNSN08505A1 (no)
TW (2) TWI520735B (no)
UY (1) UY30394A1 (no)
WO (1) WO2007141298A1 (no)
ZA (1) ZA200806411B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009122303A2 (en) * 2008-04-04 2009-10-08 Actavis Group Ptc Ehf Novel mandelate salt of fesoterodine
IT1392082B1 (it) * 2008-12-10 2012-02-09 Chemi Spa Nuove forme solide della fesoterodina fumarato
BRPI1010820A2 (pt) 2009-05-11 2019-09-24 Ratiopharm Gmbh desfesoterodina na forma de um sal de acido tartarico
EP2316432A1 (de) 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
WO2011117884A1 (en) * 2010-03-22 2011-09-29 Cadila Healthcare Limited Stable pharmaceutical compositions comprising fesoterodine
TWI590821B (zh) 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
EP2508173A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Stabilized pharmaceutical composition comprising fesoterodine
EP2508175A1 (en) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof
WO2013054337A1 (en) * 2011-07-04 2013-04-18 Cadila Healthcare Limited Extended release pharmaceutical compositions of fesoterodine
US9440910B2 (en) * 2012-05-18 2016-09-13 Alembic Pharmaceuticals Limited Reference markers for fesoterodine fumarate
ES2674811T3 (es) * 2012-07-02 2018-07-04 Hetero Research Foundation Composiciones estables de fesoterodina
JP6356684B2 (ja) 2012-11-02 2018-07-11 マレイ・アンド・プール・エンタープライゼズ・リミテッド コルヒチン誘導体の投与による心血管イベントの処置または予防
BR112015026418B1 (pt) 2013-04-16 2022-10-04 Murray And Poole Enterprises Limited Formulação de liberação prolongada de colchicina e uso da referida formulação de liberação prolongada de colchicina
DK2986280T3 (da) * 2013-04-16 2021-06-14 Murray & Poole Entpr Ltd Formuleringer med langvarig frigivelse af colchicin og fremgangsmåder til brug af samme
CZ2014400A3 (cs) 2014-06-09 2015-12-16 Zentiva, K.S. Stabilizovaná formulace fesoterodinu
CN105687154A (zh) * 2014-11-27 2016-06-22 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
WO2019011393A1 (en) 2017-07-12 2019-01-17 Rontis Hellas S.A. EXTENDED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING FESOTERODINE AND PREPARATION METHOD THEREOF
TR201721437A2 (tr) * 2017-12-25 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fesoterodi̇ni̇n modi̇fi̇ye salim sağlayan formülasyonlari
WO2019132832A1 (en) * 2017-12-25 2019-07-04 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tablet compositions of fesoterodine fumarate
KR102018495B1 (ko) * 2018-03-13 2019-09-05 충북대학교 산학협력단 과민성 방광의 치료를 위한 서방형의 이중층 정제 및 이의 제조방법
WO2019206391A1 (en) 2018-04-26 2019-10-31 Rontis Hellas S.A. Extended release pharmaceutical composition containing fesoterodine and process for the preparation thereof
CN110151720B (zh) * 2019-05-09 2019-12-17 合肥信风科技开发有限公司 含非索罗定的药用组合物及其制备方法
EP3976101A4 (en) 2019-05-31 2023-06-21 Imbria Pharmaceuticals, Inc. FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION
AU2021299197A1 (en) * 2020-06-30 2023-02-02 Imbria Pharmaceuticals, Inc. Modified release formulations of modified forms of trimetazidine
WO2023145486A1 (ja) * 2022-01-28 2023-08-03 沢井製薬株式会社 フェソテロジンフマル酸塩含有製剤の製造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044604A1 (en) * 1998-03-03 1999-09-10 Shionogi & Co., Ltd. Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate
WO2001035957A1 (de) * 1999-11-16 2001-05-25 Sanol Arznei Schwarz Gmbh Stabile salze neuartiger derivate von 3,3-diphenylpropylaminen
WO2003099268A1 (de) * 2002-05-29 2003-12-04 Grünenthal GmbH Kombination ausgewählter opioide mit anderen wirkstoffen zur therapie der harninkontinenz

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
DE10315878B4 (de) 2003-04-08 2009-06-04 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Fesoterodin und Verwendung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044604A1 (en) * 1998-03-03 1999-09-10 Shionogi & Co., Ltd. Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate
WO2001035957A1 (de) * 1999-11-16 2001-05-25 Sanol Arznei Schwarz Gmbh Stabile salze neuartiger derivate von 3,3-diphenylpropylaminen
WO2003099268A1 (de) * 2002-05-29 2003-12-04 Grünenthal GmbH Kombination ausgewählter opioide mit anderen wirkstoffen zur therapie der harninkontinenz

Also Published As

Publication number Publication date
CY1111934T1 (el) 2015-11-04
SI2029134T1 (sl) 2012-01-31
EA200802444A1 (ru) 2009-06-30
EA015909B1 (ru) 2011-12-30
PT2029134E (pt) 2011-11-02
GT200800276A (es) 2009-06-18
CU20080235A7 (es) 2011-04-26
JP2011140498A (ja) 2011-07-21
RS51973B (sr) 2012-02-29
AP2008004673A0 (en) 2008-12-31
ATE517619T1 (de) 2011-08-15
EA015909B9 (ru) 2012-03-30
PL2029134T3 (pl) 2011-12-30
KR101316773B1 (ko) 2013-10-15
AP2416A (en) 2012-06-01
EP2029134B1 (en) 2011-07-27
AU2007255408A1 (en) 2007-12-13
CU23850B1 (es) 2012-10-15
HK1128626A1 (en) 2009-11-06
TW200814992A (en) 2008-04-01
ZA200806411B (en) 2009-05-27
JP4743321B2 (ja) 2011-08-10
HRP20110776T1 (hr) 2011-11-30
JP4781489B2 (ja) 2011-09-28
CR10494A (es) 2009-01-19
KR20090026135A (ko) 2009-03-11
AR061289A1 (es) 2008-08-20
BRPI0712865B1 (pt) 2021-08-17
CA2652712C (en) 2014-04-01
DK2029134T3 (da) 2011-10-17
IL195732A (en) 2013-09-30
NL2000690A1 (nl) 2007-12-11
IL195732A0 (en) 2009-09-01
PE20080331A1 (es) 2008-06-19
NZ572616A (en) 2010-11-26
CN101466371A (zh) 2009-06-24
ES2370943T3 (es) 2011-12-23
TWI520735B (zh) 2016-02-11
WO2007141298A1 (en) 2007-12-13
AU2007255408B2 (en) 2013-03-14
TNSN08505A1 (fr) 2010-04-14
EP2029134A1 (en) 2009-03-04
MX2008015736A (es) 2009-01-09
TW201336491A (zh) 2013-09-16
TWI397409B (zh) 2013-06-01
BRPI0712865A2 (pt) 2012-12-18
PE20120476A1 (es) 2012-04-20
NO341980B1 (no) 2018-03-05
IL220800A (en) 2015-03-31
CA2652712A1 (en) 2007-12-13
UY30394A1 (es) 2007-11-30
NI200800318A (es) 2011-01-12
ECSP089010A (es) 2009-01-30
NL2000690C2 (nl) 2008-04-01
MY146574A (en) 2012-08-30
JP2009539802A (ja) 2009-11-19
CN101466371B (zh) 2011-10-05
MA30504B1 (fr) 2009-06-01

Similar Documents

Publication Publication Date Title
NO20090141L (no) Stabiliserte, farmasøytiske preparater som omfatter fesoterodin
DK2024352T3 (da) Glucopyranosylsubstituerede benzoenitrilderivater, farmaceutiske sammensætninger indeholdende sådanne forbindelser, deres anvendelse og fremgangsmåde for deres fremstilling
BR112014005134A2 (pt) composição farmacêutica de dissolução rápida
NO20075920L (no) Assosiasjon mellom ferroquin og et artemisininderivat for behandling av malaria
NO345139B1 (no) Florizinanaloger som inhibitorer av glukosekotransportør 2 og farmasøytisk sammensetning derav
DK3719018T3 (da) Purin og deazapurinderivater som farmaceutiske forbindelser
DK2068839T3 (da) Farmaceutiske sammensætninger omfattende nilotinib eller salt deraf
NO20083104L (no) Fast preparat
NO20090593L (no) Modulatorer av farmakokinetikkegenskaper til terapeutika
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
WO2007107470A3 (en) Pyrazoles as 11-beta-hsd-1
DK3133070T3 (da) Eliglustat (genz 112638) som inhibitor af glucosylceramidsyntase til anvendelse i en fremgangsmåde til behandling af fabrys eller gauchers sygdom, hvilken fremgangsmåde omfatter justering af den individuelle terapeutiske dosis i forhold til patientens p-450-metabolisme
MX369818B (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
CR10229A (es) Derivados de 1,2,4,5,-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
NO20084932L (no) Stabil farmasøytisk blanding som inneholder docetaxel og en framgangsmåte for framstilling av samme
CY1120435T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν κρυσταλλικες μορφες του μονοενυδρου υδροχλωρικου (r)-7-χλωρο-ν-(κινουκλιδινο-3-υλο) βενζο(β)θειοφαινο-2-καρβοξαμιδιου
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
CR8788A (es) Orodispersible pharmaceutical compositions for oromucosal or sublingual administration of agomelatine
EA201071235A1 (ru) Жидкая композиция для деферипрона с приятным вкусом
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
DK1987063T3 (da) Peptider og peptidderivater, fremstilling deraf samt deres anvendelse til fremstilling af en terapeutisk og/eller præventivt aktiv farmaceutisk sammensætning
CO6351721A2 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
BRPI0922870A2 (pt) uso de ao menos um composto da fórmula i, do compsoto ohod ou seus derivados farmaceuticamente aceitáveis, do composto na-ohod, composição farmacêutica e/ou nutracêutica e método cosmético
EP2196463A4 (en) PREPARATION OF 5,6-DIMETHYLXANTHONE-4-ACETIC ACID, DERIVATIVES DERIVATED THEREOF AND PHARMACEUTICAL FORMULATIONS THEREOF
ITMI20061672A1 (it) Formulazioni di acido acetilsalicilico o suoi derivati in capsule molli,esibenti elevata stabilita'

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: UCB PHARMA GMBH, DE

CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO